Generic drugmaker Teva makes $40bn offer for rival Mylan
Mylan NDEA contamination prompts Teva recall in US
Mylan board rejects Teva takeover bid
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Actavis CEO: Teva-Mylan deal could be "value-destroying" - גלובס
Mylan shares soar after takeover proposal
Teva Pharmaceutical Industries Ltd. ends its hostile bid for Mylan NV - Pittsburgh Business Times
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
$40B deal: Teva offers to buy Mylan
Mylan Should Try Teva On for Size - WSJ
Teva wins FDA nod for its generic of Mylan's EpiPen after 2-year delay | Fierce Pharma
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
Teva gains leverage in pursuit of Mylan | Pittsburgh Post-Gazette
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Mylan Rejects $40-Billion Bid from Teva | Fox Business
US lawmakers push Mylan, Teva over drug pricing probe - www.israelhayom.com
Generic EpiPen Cleared By FDA As Teva Challenges Mylan
Teva makes $40 billion offer for Mylan
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Drugmaker Teva makes $40B bid for rival Mylan
Teva offers to buy rival Mylan for $40 billion | Fortune
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Mylan Rejects Teva Takeover Bid As Too Low | Mint
